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Signal transducer and activator of transcription
Peficitinib
A B S T R A C T
Rheumatoid arthritis (RA) fibroblast-like synoviocytes (RA-FLS) play a crucial role in the pathogenesis of RA.
RA-FLS display passive pro-inflammatory responses and self-directed aggressive responses, such as pro-in-
flammatory mediator production, reduced apoptosis and formation of a thickened synovial lining. Evidence
suggests a role for Janus kinase (JAK)-signal transducer and transcriptional activator (STAT) signaling in the
passive response but the aggressive behavior of RA-FLS is poorly understood.
The pharmacologic effects of the novel JAK inhibitor, peficitinib, on cytokine-induced intracellular signaling
and self-directed aggressive behavior of RA-FLS (e.g., increased expression of apoptosis-resistant genes and
sodium nitroprusside-induced apoptosis) were investigated and compared with approved JAK inhibitors. RA-FLS
assembly to form a lining-like structure and pro-inflammatory mediator production was investigated in three-
dimensional (3D)-micromass culture.
Peficitinib inhibited STAT3 phosphorylation in RA-FLS following induction by interferon (IFN)-α2b, IFN-γ,
interleukin (IL)-6, oncostatin M, and leukemia inhibitory factor in a concentration-related manner, and was
comparable to approved JAK inhibitors, tofacitinib and baricitinib. Peficitinib and tofacitinib suppressed au-
tocrine phosphorylation of STAT3 and expression of apoptosis-resistant genes, and promoted cell death. In 3D-
micromass culture, peficitinib reduced multi-layered RA-FLS cells to a thin monolayer, an effect less pronounced
with tofacitinib. Both compounds attenuated production of vascular endothelial growth factor-A, matrix me-
talloproteinases, IL-6 and tumor necrosis factor superfamily-11.
This study confirmed the pathogenic role of uncontrolled JAK-STAT signaling in the aggressive and passive
responses of RA-FLS that are critical for RA progression. The novel JAK inhibitor peficitinib suppressed the pro-
inflammatory behavior of RA-FLS, accelerated cell death and abrogated thickening of the synovium.
1. Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease char-
acterized by synovial inflammation and joint destruction. Under normal
conditions, the cells of the synovial membrane (fibroblast-like syno-
viocytes; FLS) assure the integrity of joints by controlling the compo-
sition of the synovial fluid and extracellular matrix of the joint lining. In
RA, chronic inflammation causes phenotypic conversion of FLS to RA-
FLS, which proliferate, leading to a thickened synovial membrane, or
“pannus”, and subsequent joint destruction. RA-FLS produce pro-in-
flammatory mediators that degrade and remodel the tissue (Bottini and
Firestein, 2013; Cho et al., 2002; Lefevre et al., 2015) and tumor ne-
crosis factor (TNF) superfamily-11 (TNFSF11; or receptor activator of
nuclear factor κB ligand: RANKL), involved predominantly in bone
erosion (Takayanagi et al., 2000).
Biological cytokine inhibitors, such as anti-TNF-α and anti-
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interleukin (IL)-6 receptor antibodies, have revolutionized the man-
agement of RA over the past two decades (Wang et al., 2014). However,
RA pathogenesis is multifactorial and complex, and optimization of
management requires broader control of inflammatory cytokines and
processes. Another approach to RA therapy would be to target the ag-
gressive behavior of RA-FLS, such as increased survival, adhesion and
invasiveness, and lining cell condensation to produce the thickened,
hyperplastic pannus (Bottini and Firestein, 2013; Kiener et al., 2006).
Notably, upregulation of apoptosis-resistant genes drives the develop-
ment of hyperplasia (Bartok and Firestein, 2010).
The Janus kinase (JAK) family (JAK1, JAK2, JAK3 and tyrosine
kinase-2: TYK2) of non-receptor tyrosine kinases plays a crucial role in
cytokine signaling implicated in the pathogenesis of RA. Activated JAKs
recruit signal transducer and activator of transcription (STAT) proteins
(STAT1, 2, 3, 4, 5A, 5B and 6), which translocate to the nucleus and
activate their target genes. Currently, more than 40 different cytokines
and growth factors have been shown to activate specific combinations
of JAKs and STATs (Nakayamada et al., 2016). STAT3 may be im-
portant for RA pathogenesis, particularly in synovitis, although the
specific role of STAT proteins remains to be clarified (Gao et al., 2015).
A number of JAK inhibitors have been marketed as new therapies
for RA (Nakayamada et al., 2016). Tofacitinib inhibits JAK1, JAK2,
JAK3 and to a lesser extent TYK2. Baricitinib inhibits JAK1 and JAK2
with better selectivity than JAK3 (Nakayamada et al., 2016). Peficitinib
is a novel pan-JAK inhibitor that inhibits JAK1, JAK2, JAK3 and TYK2
(Ito et al., 2017). The efficacy and safety profile of these compounds in
clinical trials highlight the critical role of JAK-STAT pathways in the
pathogenesis of RA and emphasize the potential for JAK inhibitors to
provide alternative therapies in the treatment of RA (Nakayamada
et al., 2016). While there is clear evidence of a role for JAK-STAT sig-
naling in the cytokine response and migration of RA-FLS (Diller et al.,
2019; Ikari et al., 2019), the role of the pathway in the self-directed
aggressive behavior of RA-FLS is poorly understood.
The present study investigates the pharmacologic profile of pefici-
tinib on JAK-STAT signaling in RA-FLS and its effect on sodium ni-
troprusside-induced apoptosis. Using a three-dimensional (3D) culture
system that recapitulates the diseased phenotypes in RA-FLS, we further
investigated the effect of peficitinib on the spontaneous production of
pro-inflammatory mediators and formation of a thickened lining-like
cell structure.
2. Materials and methods
2.1. Study approval
In this study, no animal experimentation occurred, with no animal
ethics committee required. Ethical approval for experiments with
human samples in this study was granted by the Ethics Committee of
Kyoto University Graduate School and the Faculty of Medicine (ap-
proval number: G418), and Astellas Research Ethics Committee (ap-
proval number: 120182). Informed consent was obtained from all pa-
tients prior to sample collection.
2.2. Patient-derived FLS
RA and osteoarthritis (OA) were diagnosed according to the criteria
of the American College of Rheumatology (Altman et al., 1986; Arnett
et al., 1988). Synovial tissues were obtained from patients with OA and
RA undergoing orthopedic surgery. RA-FLS were isolated from synovial
tissue as described previously (Emori et al., 2017) and maintained in
Dulbecco's modified Eagle's medium (Gibco, Paisley, UK) supplemented
with 10% heat-inactivated fetal bovine serum (FBS) (Hyclone from GE
Healthcare, Buckinghamshire, UK or FBS from Biosera, Kansas City,
MO), 100 units/ml of penicillin, and 100 μg/ml of streptomycin sulfate
(Nacalai Tesque, Kyoto, Japan) in an incubator at 5% CO2 at 37 °C. FLS
that had been passaged 4–10 times after the start of the culture were
used as isolated FLS.
2.3. Test reagents
Peficitinib, tofacitinib and baricitinib were synthesized in Astellas
Pharma Inc., and were stocked as 10 mM dimethyl sulfoxide (DMSO)
solution. The compounds were diluted in culture medium supple-
mented with 1% DMSO at ten times the desired concentration and
added to the wells of a 96-well plate at one-tenth of the final volume. IL-
6 receptor-blocking antibody (MAB227) and isotype-matched control
antibody (MAB002) were purchased from R&D Systems (Minneapolis,
MN) and diluted in culture medium.
2.4. Immunofluorescent staining
Immunofluorescent staining was performed as described previously
(Emori et al., 2017). Acquisition of microscopy images was performed
by NIS-Elements (version 3.2, Nikon Corporation, Tokyo, Japan). The
primary and secondary antibodies used in this study were as follows:
rabbit immunoglobulin (Ig)G isotype control (clone DA1E, Cell Sig-
naling Technology, Danvers, MA), anti-phosphorylated STAT3 (rabbit
monoclonal antibody, clone EP2147Y, Abcam, Cambridge, UK), anti-
phosphorylated STAT1 (rabbit monoclonal antibody, clone 58D6, Cell
Signaling Technology), anti-phosphorylated STAT4 (rabbit monoclonal
antibody, clone D2E4, Cell Signaling Technology), anti-phosphorylated
STAT5 (rabbit monoclonal antibody, clone C71E5, Cell Signaling
Technology), Alexa flour 488-conjugated anti-rabbit IgG (Life Tech-
nologies, Carlsbad, CA). DAPI (4′,6-diamidino-2-phenylindole, Nacalai
Tesque, Kyoto, Japan) was added at 1 μg/ml to the secondary antibody
solution.
2.5. Cell-based enzyme-linked immunosorbent assay (ELISA)
RA-FLS (2 × 104 cells) were seeded in 96-well plates and incubated
in a CO2 incubator. The following day, the culture supernatants were
exchanged with fresh medium (40 μl). After addition of 10 μl of a
10 × solution of test compounds or test antibodies, the plates were
further incubated for 20 min. Ligand stimulation was performed by
adding twice the concentration of the indicated ligands (50 μl) and
incubating for 20 min. The cells were then fixed in phosphate buffered
saline (PBS)-buffered 8% formaldehyde (100 μl) for 10–20 min, washed
with PBS and permeabilized by incubation in ice-cold methanol
(100 μl) for 10 min. After washing with PBS extensively, the cells were
blocked with PBS-buffered 1% bovine serum albumin (BSA) (150 μl) for
1 h and stained with anti-phosphorylated STAT3 (rabbit monoclonal
antibody; EP2147Y; Abcam), diluted 1:500 in PBS-buffered 1% BSA
(50 μl), for 2 h. The cells were washed with PBS and further incubated
with horseradish peroxidase (HRP)-linked anti-rabbit IgG (Cell sig-
naling technology), diluted 1:2000 in PBS-buffered 1% BSA, for 1 h.
The signal was developed using 1-Step Ultra 3,3′,5,5′-tetra-
methylbenzidine-ELISA (50 μl, Thermo Fisher Scientific, Waltham, MA)
and measured using a microplate reader after addition of 4N sulfuric
acid (50 μl, Nacalai Tesque, Kyoto Japan). The recombinant human
cytokines were purchased and used as indicated: interferon (IFN)-α2b
(1000 ng/ml, BioVision, Milpitas, CA), IFN-γ (100 ng/ml, R&D
Systems), IL-6 (200 ng/ml, R&D Systems), IL-15 (100 ng/ml, R&D
Systems), IL-21 (100 ng/ml, PeproTech, Rocky Hill, NJ), TNF-α
(100 ng/ml, R&D Systems), leukemia inhibitory factor (LIF) (100 ng/
ml, R&D Systems), oncostatin M (OSM) (100 ng/ml, R&D Systems), sIL-
6 receptor (200 ng/ml, PeproTech).
2.6. Determination of phosphorylated STAT3 and total STAT3 protein
levels
Test compounds were diluted 1:10 in medium supplemented with
1% DMSO and dispensed into 6-well plates (0.2 ml/well), and OA- or
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RA-FLS cell suspensions were added (2.8–6.0 × 104 cells/ml, 1.8 ml/
well). For the control well, 1.8 ml of cell suspension was added with
0.2 ml of medium supplemented with 1% DMSO. The cells were grown
in a CO2 incubator for 6 days to reach confluence. Cellular phos-
phorylated (p)STAT3 and total STAT3 levels were examined in cell
lysates prepared from the cells (23 μg) using a STAT3 (pY705) plus total
STAT3 ELISA Kit (Abcam) and determined from the absorbance at
450 nm according to the manufacturer's instructions. Because the kit
was designed as a semi-quantitative measurement method that did not
utilize standard curves, the absorbance values were compared using
statistical analyses.
2.7. Gene expression analysis
Total RNA was extracted from cells using an RNeasy plus mini RNA
extraction kit (Qiagen, Hilden, Germany). Complementary DNA was
synthesized from 50 ng of RNA using the SuperScript IV first-strand
synthesis system (Thermo Fisher Scientific) and subjected to real-time
polymerase chain reaction (PCR) in a Quadro studio real-time PCR
system (Applied Biosystems, Foster City, CA) using TaqMan gene ex-
pression master mix (Applied Biosystems). The following TaqMan pri-
mers were purchased from Applied Biosystems and used in real-time
PCR: BCL2 (Hs00608023_m1), MCL1 (Hs01050896_m1), GAPDH
(Hs02786624_g1). Gene expression levels were also determined by
microarray analysis using SurePrint G3 Human GE 8 × 60K v2
Microarray (Agilent technologies, Santa Clara, CA) with total RNA
prepared using the procedure described above and analyzed by
GeneSpring GX (Agilent technologies).
2.8. Apoptosis assay
OA- and RA-FLS (2 × 104 cells) were seeded in 96-well plates and
cultured overnight. The culture medium was replaced with fresh
medium (80 μl) and 10 × solutions of inhibitors or 1% DMSO (10 μl;
control) and 20 mM of sodium nitroprusside (10 μl) (Sigma-Aldrich, St
Louis, MO) were added to the wells. The plates were incubated for 5 h
in a CO2 incubator. The rate of apoptosis was determined by measuring
the remaining viable cells in the 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) assay using the CellTiter-96 non-
radioactive cell proliferation assay (Promega, Madison, WI).
2.9. 3D-micromass culture and quantification of the lining-like structure
Compounds and blocking antibodies in the 3D-micromass culture
were examined as previously described (Emori et al., 2017) with a
slight modification. To activate IL-6-mediated signaling, recombinant
sIL-6 receptor (PeproTech) was added to the culture medium (50 ng/
ml) during the last two weeks of incubation. Thickness of the lining-like
structure was measured using image analysis of phalloidin-stained
sections of the 3D-micromass architecture as described previously
(Emori et al., 2017).
2.10. Western blotting
Preparation of cell lysates from 3D-cultured FLS and subsequent
western blotting analyses were performed as described previously
(Emori et al., 2017). The antibodies used in the experiments were as
follows: anti-pSTAT3 (rabbit monoclonal antibody; EP2147Y; Abcam),
anti-human STAT3 (rabbit monoclonal antibody; D1B2J; Cell Signaling
Technology), anti-human integrin α9 (rabbit monoclonal antibody;
EPR9722; Abcam), anti-human cadherin-11 (rabbit polyclonal anti-
body; LS-B2308; LSBio, Seattle, WA), anti-human TNFSF11 (goat
polyclonal antibody; AF626; R&D Systems), anti-human GAPDH
(mouse monoclonal antibody; 6C5; Santacruz Biotechnology, Dallas,
TX), HRP-conjugated anti-mouse IgG (NA931V; GE Healthcare) and
HRP-conjugated anti-rabbit IgG (NA934V; GE Healthcare).
2.11. ELISA for secreted proteins
The amount of secreted protein in culture supernatants was de-
termined by ELISA using the following commercially available kits:
matrix metalloproteinase (MMP)-1 (human total MMP-1 DuoSet ELISA;
R&D Systems), MMP-3 (human total MMP-3 DuoSet ELISA; R&D
Systems), IL-6 (human IL-6 DuoSet ELISA; R&D Systems), vascular en-
dothelial growth factor-A (VEGF-A, human VEGF-A ELISA kit;
RayBiotech, Norcross, GA). Half of the detection limit value indicated in
the instruction was adopted when the sample value was below the
lower limit of quantification.
2.12. Statistical analysis
Statistical analyses and calculation of IC50 values were performed
using GraphPad Prism 7 software (GraphPad Software, La Jolla, CA). A
P value < 0.05 was considered statistically significant.
3. Results
3.1. Phosphorylation of STAT3 is enhanced in RA synovial tissue
To determine the JAK-STAT pathways activated in RA synovial
tissues, we conducted immunofluorescent staining of frozen RA tissue
sections using antibodies against pSTAT1, pSTAT3, pSTAT4 and
pSTAT5 in combination with DAPI. Staining was also performed on OA
tissue sections for comparison. pSTAT3-positive cells were widely and
abundantly distributed across the hyperplastic region in RA tissue but
were rare in OA tissue (Fig. 1A). In addition, pSTAT3 staining over-
lapped with DAPI staining in RA tissue, indicating nuclear localization
(Fig. 1B). Further immunofluorescence analysis is needed to investigate
whether the unphosphorylated STAT3 level is also increased in RA
tissue compared with OA tissue. In contrast, there was no apparent
pSTAT1, pSTAT4 or pSTAT5 staining in either RA or OA tissue (data not
shown). These results indicate that STAT3 is activated in RA synovium,
suggesting a role for STAT3 in the pathogenesis of RA.
3.2. JAK inhibitors block STAT3 phosphorylation induced by various
cytokines in RA-FLS
To identify the cytokines that induce pSTAT3 in RA tissue, we ex-
amined the ability of various cytokines to induce STAT3 phosphoryla-
tion in RA-FLS isolated from RA tissue. RA-FLS were stimulated with
various cytokines and the level of pSTAT3 determined. Phosphorylation
of STAT3 was markedly induced following stimulation with IFN-α2b
(1000 ng/ml), IFN-γ (100 ng/ml), LIF (100 ng/ml) and OSM (100 ng/
L), but not TNF-α (100 ng/ml), IL-15 (100 ng/ml) and IL-21 (100 ng/
ml) (Fig. 2A). Stimulation with IL-6 (200 ng/ml) also increased levels of
pSTAT3, and addition of sIL-6 receptor (200 ng/ml) further increased
these levels (Fig. 2A). These results indicate that IFN-α2b, IFN-γ, OSM,
LIF, IL-6 and sIL-6 receptor may contribute to the constitutive phos-
phorylation of STAT3 in RA tissue.
We subsequently compared the effect of peficitinib with tofacitinib
and baricitinib on the induction of pSTAT3 by IFN-α2b, IFN-γ, LIF and
OSM in RA-FLS using cell-based ELISA. RA-FLS were treated with var-
ious concentrations of JAK inhibitors, stimulated with cytokines and
subjected to cell-based ELISA to determine the levels of pSTAT3. All the
JAK inhibitors blocked the induction of pSTAT3 by the cytokines tested
in a similar concentration-related manner (Fig. 2B). Although their 50%
inhibition concentration (IC50) values differed slightly, the significance
of this difference was unclear because of wide 95% confidence intervals
(Table 1).
The IC50 values were calculated by non-linear curve fitting in the
assays described in Fig. 2B. The geometric mean of the IC50 values from
four independent experiments is shown with 95% confident intervals.
The specific JAK family members associated with the indicated
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cytokine receptors are shown according to previous reports (Banerjee
et al., 2017; Heinrich et al., 1998).
IC50, half maximal inhibitory concentration; IFN, interferon; IL-6,
interleukin-6; JAK, Janus kinase; LIF, leukemia inhibitory factor; OSM,
oncostatin M; sIL-6, soluble interleukin-6.
3.3. JAK inhibitors suppress enhanced phosphorylation of STAT3 and
promote apoptosis of RA-FLS
We next examined whether JAK activation is involved in the en-
hanced phosphorylation of STAT3. OA- and RA-FLS were grown to
confluence in medium supplemented with or without peficitinib or to-
facitinib at the various concentrations, and pSTAT3 and total STAT3
protein levels in lysates prepared from the cells were then determined
using ELISA. Phosphorylated STAT3 and total STAT3 protein levels in
RA-FLS were significantly higher than those in OA-FLS, and treatment
of RA-FLS with peficitinib and tofacitinib decreased the elevated levels
of pSTAT3, indicating that enhanced phosphorylation of STAT3 in RA-
FLS is JAK dependent (Fig. 3A). In addition, peficitinib, but not tofa-
citinib, tended to reduce total STAT3 protein levels at 1000 nM
(Fig. 3A).
Activation of STAT3 imparts anti-apoptotic ability to RA-FLS
through upregulation of the B-cell leukemia/lymphoma 2 protein
(BCL2) family of anti-apoptotic genes (Lee et al., 2013; Zhao et al.,
2017). Therefore, we determined gene expression levels of BCL2 and
myeloid cell leukemia sequence 1 (MCL1) using real-time PCR with
RNA prepared from the above cells. Compared with OA-FLS, RA-FLS
displayed increased expression of these anti-apoptotic genes, and
treatment with peficitinib and tofacitinib attenuated this increase, in-
dicating that RA-FLS employ increased expression of anti-apoptotic
genes in a JAK-dependent manner, and that autonomous activation of
the JAK-STAT pathway is responsible for the enhanced expression of
anti-apoptotic genes in RA-FLS (Fig. 3B). We also determined whether
treatment with JAK inhibitors promotes cell death in RA-FLS via
sodium nitroprusside, which generates nitric oxide to induce apoptosis
(Xie et al., 1997). RA-FLS grown in 96-well plates were treated with the
JAK inhibitors in combination with soluble nitroprusside for 5 h. The
degree of cell death was calculated according to viability in the MTT
assay (Fig. 3C). Treatment of RA-FLS with the JAK inhibitors them-
selves did not cause apparent cell death (Fig. 3C, white bars). However,
addition of 2 mM soluble nitroprusside to DMSO-treated RA-FLS caused
a 38.4% increase in cell death compared to the DMSO only control. Cell
death increased by 63.8% and 52.8% when soluble nitroprusside was
combined with peficitinib and tofacitinib, respectively, compared to the
control treated with the respective JAK inhibitors alone (Fig. 3C, black
bars). These results indicate that JAK inhibitors can accelerate soluble
nitroprusside-induced apoptosis in RA-FLS.
3.4. JAK inhibitors prevent formation of a hyperplastic lining-like structure
by RA-FLS grown in 3D-micromass culture
Given that the anti-apoptotic ability of RA-FLS is considered one of
the drivers of synovial lining hyperplasia in RA, we examined the action
of JAK inhibitors on the formation of the hyperplastic lining-like
structure using a previously described 3D-micromass culture system
(Emori et al., 2017). Isolated RA-FLS were embedded in Matrigel and
cultured in 3D-micromass for 3 weeks with various concentrations of
peficitinib or tofacitinib. To promote the response of RA-FLS to au-
tonomously produced IL-6, sIL-6 receptor was added to the culture
during the last 2 weeks. The resultant architectures were freeze-fixed,
sectioned and stained with fluorescent-labeled phalloidin to visualize
the lining-like structure. Control RA-FLS grown in the 3D-culture au-
tonomously formed multi-layered lining-like cell condensation (Fig. 4),
a structure that was abrogated and reduced to almost a thin mono-
layered lining following treatment with peficitinib (Fig. 4). Subsequent
quantitative analysis of the microscopic images revealed that treatment
with peficitinib caused a concentration-related reduction in the thick-
ness of the lining-like structure (up to 78.0% of the DMSO control;
Fig. 1. Constitutive activation of STAT3 in RA
synovial tissue. (A) Fluorescent micrographs of
phosphorylated STAT3 protein in RA and OA syno-
vial tissue. Frozen sections from OA (upper) and RA
tissue (lower) were stained with an antibody against
pSTAT3 and Alexa Fluor 488-labeled secondary an-
tibody and counterstained with DAPI. The sections
were photographed under a fluorescent microscope
at the same exposure time. Representative images of
tissues from three independent patients are shown.
Scale bars: 200 μm. (B) High magnification images of
the RA tissues in (A). Scale bars: 100 μm.
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Fig. 4). Although not significant, tofacitinib displayed a clear trend
towards decreasing the thickness of the lining-like structure (up to
88.8% of the DMSO control; Fig. 4).
We also determined the pSTAT3 levels in the cells grown in the 3D-
micromass culture. Cell lysates prepared from the architectures were
subjected to western blotting using an antibody against pSTAT3 fol-
lowed by reprobing with an antibody against total STAT3 and GAPDH.
The marked phosphorylation of STAT3 observed in the DMSO control
was decreased by a similar extent following treatment with peficitinib
and tofacitinib (Fig. 4). The decrease of total STAT3 protein observed
Fig. 2. Inhibitory profile of peficitinib,
tofacitinib and baricitinib against
pSTAT3 induction by various cytokines
in RA-FLS. (A) Induction of pSTAT3 in RA-
FLS by various cytokines. RA-FLS, cultured
in 96-well plates, were stimulated with the
indicated cytokines and subjected to cell-
based ELISA to determine pSTAT3 levels.
Data represent the mean value of triplicate
assays. Patient 1 and 2 indicate assays using
RA-FLS from independent patients. (B)
Inhibitory profile of peficitinib, tofacitinib
and baricitinib against pSTAT3 induction
by various cytokines. RA-FLS were stimu-
lated with the indicated cytokines with or
without peficitinib, tofacitinib or bar-
icitinib. pSTAT3 levels were determined
using cell-based ELISA and expressed as a
percentage of the DMSO control. IC50 values
of each compound were calculated using
non-linear curve fitting and are summarized
in Table 1. The experiments were per-
formed using RA-FLS from three to five
patients and representative fitted curves are
shown. Each plot indicates the mean value
of duplicate assays. Open circle: peficitinib,
open square: tofacitinib, open triangle:
baricitinib. IFN, interferon; IL, interleukin;
JAK, Janus kinase; LIF, leukemia inhibitory
factor; OSM, oncostatin M; sIL, soluble in-
terleukin; TNF, tumor necrosis factor.
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following treatment with peficitinib in plate-cultured RA-FLS (Fig. 3A)
was also observed in the cells grown in the 3D-micromass culture
(Fig. 4). Subsequently, we investigated the effect of an IL-6 receptor
antibody in the same 3D-culture assay. Like peficitinib, IL-6 receptor
antibody blocked pSTAT3 induction by IL-6 plus sIL-6 receptor in RA-
FLS using cell-based ELISA (Fig. 4) but, in contrast to the effect ob-
served for JAK inhibitors, there was no apparent reduction in the lining
thickness following treatment of the architectures with the IL-6 receptor
Table 1
JAK inhibitor IC50 values for inhibition of cytokine-stimulated pSTAT3 induction in RA-FLS.
Ligand/cytokine Associated JAK IC50 (nM) [95% confidence interval] (n)
Peficitinib Tofacitinib Baricitinib
IFN-α2b JAK1, TYK2 11.95 [7.35 to 19.42] (n = 4) 19.47 [7.08 to 53.54] (n = 4) 7.59 [3.32 to 17.32] (n = 4)
IFN-γ JAK1, JAK2 62.27 [25.04 to 154.9] (n = 4) 75.82 [46.7 to 123.1] (n = 4) 23.73 [16.22 to 34.72] (n = 4)
IL-6 plus sIL-6 receptor JAK1, JAK2, TYK2 81.68 [51.53 to 129.5] (n = 5) 164.3 [113.4 to 238.0] (n = 5) 27.04 [14.71 to 49.7] (n = 4)
OSM JAK1, JAK2, TYK2 149.1 [84.85 to 262.1] (n = 5) 302.8 [199.1 to 460.5] (n = 5) 69.8 [58.38 to 83.46] (n = 4)
LIF JAK1, JAK2, TYK2 31.03 [14.43 to 66.71] (n = 4) 83.3 [68.18 to 101.8] (n = 4) 36.41 [28.05 to 47.25] (n = 3)
Fig. 3. Effect of JAK inhibitors on increased le-
vels of pSTAT3 and soluble nitroprusside-in-
duced apoptosis induced in RA-FLS. (A and B)
Effect of JAK inhibitors on increased levels of
pSTAT3 and anti-apoptotic gene expression normal-
ized to that of GAPDH in RA/OA-FLS. Data are ex-
pressed as the mean and S.E.M. Statistical analyses
were performed using Student's t-test (OA-FLS with
DMSO vs RA-FLS with DMSO) and Dunnett's test
using within subject error (RA-FLS with DMSO vs
RA-FLS with compounds at the indicated concentra-
tions). **/##P < 0.01; ns, not significant. (C) Effect
of JAK inhibitors on cell death of RA-FLS induced by
soluble nitroprusside. Data are expressed as the
mean percentage of the non-treated DMSO control
and S.E.M. Statistical analyses were performed using
a Student's t-test (non-treated control with DMSO vs
apoptosis-induced RA-FLS with DMSO) and
Dunnett's test using within subject error (RA-FLS
with DMSO vs RA-FLS with compounds at the in-
dicated concentrations). *P < 0.05;
**/##P < 0.01; ns, not significant. (A) n = 4; (B)
n = 4; (C) n = 6. BCL, B-cell leukemia; FLS, fibro-
blast-like synoviocytes; MCL, myeloid cell leukemia;
OA, osteoarthritis; pefi, peficitinib; pSTAT, phos-
phorylated signal transducer and transcriptional ac-
tivator; RA, rheumatoid arthritis; SNP, sodium ni-
troprusside; tofa, tofacitinib.
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antibody (Fig. 4). In addition, treatment of 3D-cultured RA-FLS with the
IL-6 receptor antibody had no effect on the pSTAT3 or STAT3 protein
levels (Fig. 4).
Because integrin α9 and cadherin-11 reportedly mediate aggressive
cell condensation into the lining-like structure observed in this system
(Emori et al., 2017; Kiener et al., 2006), we also determined the effect
of JAK inhibitors on integrin α9 and cadherin-11 protein levels. How-
ever, JAK inhibitors had no effect on integrin α9 or cadherin-11 protein
levels (Fig. 4), indicating that the effect of JAK inhibitors on the as-
sembly of lining cell condensation is independent of integrin α9 and
cadherin-11.
3.5. JAK inhibitors ameliorate the production of pro-inflammatory
mediators by RA-FLS grown in 3D-micromass culture
We examined the effect of JAK inhibitors and the IL-6 receptor
antibody on the production of pro-inflammatory mediators by RA-FLS
cultured in 3D-micromass. To do this, we determined the concentra-
tions of MMP-1, MMP-3, IL-6 and VEGF-A in the supernatants of the 3D-
micromass culture performed as described in Materials and Methods.
While there was a significant decrease in these mediators in the cell
supernatants following treatment with JAK inhibitors, particularly pe-
ficitinib (Fig. 5A; tofacitinib did not significantly reduce VEGF-A), there
was no such reduction following treatment with the IL-6 receptor an-
tibody (Fig. 5B). In addition, western blotting of the lysates from the
Fig. 4. Effect of JAK inhibitors on self-directed lining-
like cell condensation of RA-FLS in 3D-micromass
culture. RA-FLS were pretreated with peficitinib (pefi) or
tofacitinib (tofa) at the indicated concentrations (A) or
10 μg/ml of interleukin-6R antibody (IL-6 receptor Ab) (B)
and maintained in 3D-micromass culture with medium
containing the corresponding reagents. An equal amount
of DMSO or isotype-matched control antibody (iso) was
added to the control. (A and B) The thickness of the lining-
like structure of the resultant architectures was calculated
using image analyses and expressed as the mean and
S.E.M. Statistical analyses were performed using a
Dunnett's test using within subject error (A) and paired t-
test (B). **P < 0.01; ns, not significant. (A) n = 5; (B)
n = 5. (C) Typical images of the lining-like structure
formed by RA-FLS following treatment with DMSO (left)
or peficitinib (1000 nM, right) with DAPI staining. Scale
bar: 50 μm. (D) Western blotting of the lysates from the
resultant architectures was performed using antibodies
against the indicated molecules. Representative data from
RA-FLS from three to five independent patients are shown.
Lower panel indicates original gel blots of asterisked
(*/**) images in upper panel. Pt.1-Pt.5 indicates patient
ID. Bands indicated by boxes were cropped and used in the
upper panel. (E) Inhibition of pSTAT3 induction by IL-6
plus sIL-6 receptor using an IL-6 receptor antibody in RA-
FLS was analyzed using cell-based ELISA and the values
were converted to a percentage of the control value from
non-treated cells. Data represent the mean of triplicate
assays. Closed circle: IL-6 receptor antibody, open circles:
isotype-matched control. Non-linear fitted curves for the
IL-6 receptor antibody and isotype-matched control are
shown as solid and dashed lines, respectively. pSTAT,
phosphorylated signal transducer and transcriptional ac-
tivator.
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3D-cultured cells showed that treatment with JAK inhibitors decreased
TNFSF11/RANKL protein levels, which were not altered by treatment
with the IL-6 receptor antibody (Fig. 5C). These results indicate that
JAK inhibitors suppress activation of STAT3, ameliorate the assembly of
hyperplastic lining cell condensation and inhibit production of pro-in-
flammatory mediators in RA-FLS, which cannot be achieved by specific
blockade of IL-6 receptor.
3.6. Cytokines and growth factors possibly contribute to formation of
hyperplastic lining-like structure associated with RA-FLS
To explore the possible factors involved in the formation of hyper-
plastic lining-like structure, we determined gene expression levels of
various cytokines and growth factors known to induce STAT3 phos-
phorylation in RA- and OA-FLS grown in 3D-micromass. As a result,
although not significant, RA-FLS displayed more abundant expression
of IL-6, LIF, OSM, platelet-derived growth factor (PDGF) A, PDGFC and
PDGFD than did OA-FLS. This suggests that upregulation of these
factors possibly contributes to the formation of hyperplastic lining-like
structure in an autocrine manner in RA-FLS (Fig. 6).
4. Discussion
The JAK-STAT pathway is the major mechanism mediating cytokine
signaling and cellular response to extracellular stimuli. While the pri-
mary action of JAK inhibitors on RA-FLS may be to regulate their
passive response to pro-inflammatory cytokines, we hypothesized that
the aggressive behavior of RA-FLS may also be associated with ex-
cessive activation of JAK-STAT signaling and thus a target for JAK in-
hibition. We investigated this by determining the effect of JAK in-
hibitors on the disease-associated phenotypes of RA-FLS.
We found that phosphorylation of STAT3 was enhanced in RA tissue
(Fig. 1). Interestingly, RA-FLS retained high STAT3 phosphorylation
after isolation from the synovial environment. In addition, the phos-
phorylation of STAT3 was suppressed by JAK inhibitors (Figs. 3A and
4D). These results suggest that enhanced basal STAT3 activity is one of
Fig. 5. Effect of JAK inhibitors on autonomous
expression of pro-inflammatory mediators in RA-
FLS in 3D-micromass culture. (A and B) The su-
pernatants of RA-FLS cultured in 3D-micromass were
obtained at the end of the experiments described in
Fig. 4 and were analyzed using ELISA for the in-
dicated mediators. Data represent the mean and
S.E.M. (A) n = 5; (B) n = 5. Statistical analyses were
performed using a Dunnett's test using within subject
error (A) and paired t-test (B). *P < 0.05;
**P < 0.01; ns, not significant. (C) The cell lysates
of the micromass architectures prepared in Fig. 4
were analyzed by western blotting using antibodies
against the indicated proteins. IL, interleukin; iso,
isotype-matched control; MMP, matrix metallopro-
teinase; pefi, peficitinib; TNFSF11, tumor necrosis
factor superfamily-11; tofa, tofacitinib; VEGF, vas-
cular endothelial growth factor.
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the abnormal properties of RA-FLS, and is induced by JAK-mediated
cytokine signaling.
Platelet-derived growth factor and epidermal growth factor are re-
portedly involved in the autocrine phosphorylation of STAT3 in isolated
RA-FLS (Krause et al., 2002). Furthermore, RA-FLS are known to pro-
duce their own array of cytokines, such as IL-6, IL-15, IL-32 and IL-33
(Lefevre et al., 2015), found at higher levels in the synovial fluid of RA
compared with OA patients (Altobelli et al., 2017; Hong et al., 2011;
Kurowska et al., 2002; Matsuyama et al., 2012; Moon et al., 2012).
Some of these cytokines might cooperatively contribute to maintaining
enhanced STAT3 activity in an autocrine manner. Our gene expression
analysis showed upregulation of IL-6, LIF and OSM expression in RA-
FLS compared with OA-FLS grown in 3D-micromass. Signaling through
these cytokines is inhibitable by JAK inhibitors; thus, we propose that
simultaneous inhibition of these multiple cytokines possibly accounts
for the superior effect of JAK inhibitors compared with specific cytokine
blockade by anti-cytokine antibody. The gene expression analysis also
revealed a potential contribution of several types of PDGF in hyper-
plastic behavior of RA-FLS, but we have not yet determined if blockade
of PDGF occurs in our 3D-assay system. In addition to the enhancement
of STAT3 phosphorylation, higher levels of total STAT3 protein were
also observed in RA-FLS. This may be explained by the existence of
hypo-methylated loci in the STAT3 gene in RA-FLS, which can increase
STAT3 expression (Nakano et al., 2013).
One important finding in this study is that JAK inhibitors promoted
RA-FLS cell death (Fig. 3). RA-FLS expressed higher levels of the anti-
apoptotic genes, BCL2 and MCL1, compared with OA-FLS (Fig. 3B).
This is consistent with a previous report showing that RA-FLS have
higher levels of the BCL2 gene and are more resistant to soluble ni-
troprusside-induced apoptosis than OA-FLS (Lee et al., 2013), and
provides the molecular basis underlying enhanced survival of RA-FLS.
Given that these genes are regulated by STAT3 (Lee et al., 2013; Yue
et al., 2015; Zhao et al., 2017) and JAK inhibitors suppressed the en-
hanced phosphorylation of STAT3 and accelerated RA-FLS cell death
(Fig. 3A and C), it is likely that the cytokine milieu associated with RA
potentiates the intrinsic pro-survival ability of RA-FLS and causes local
accumulation of these cells, leading to synovial lining hyperplasia.
Previous reports also indicate that extracellular stimuli such as IL-17
and IL-22 can decrease the rate of apoptosis in RA-FLS via the JAK-
STAT3 pathway (Lee et al., 2013; Zhao et al., 2017). Considering the
report showing that treatment of RA-FLS with JAK inhibitors itself does
not induce apoptosis in RA-FLS (Diller et al., 2019), JAK inhibitors may
work with environmental stress to accelerate apoptosis.
Using a 3D-micromass culture system, we found that JAK inhibitors
attenuated self-directed formation of a hyperplastic lining-like structure
by RA-FLS (Fig. 4). This provides direct evidence that JAK inhibitors
can abrogate establishment of lining hyperplasia and development of
pannus in RA. In this system, the thickness of lining by OA-FLS is re-
ported to be 66.6% of that by RA-FLS. Our data show that the thickness
by RA-FLS treated with peficitinib and tofacitinib was dose-related, and
decreased up to 78.0% and 88.8% of DMSO control, respectively. Al-
though we have not examined the effect of JAK inhibitors on the for-
mation of lining-like structure by OA-FLS, these results may suggest
that JAK inhibitors attenuate disease-related hyperplastic activity in
RA-FLS and lining hyperplasia. The effect of JAK inhibition on lining
hyperplasia was also proven in a rat arthritis model treated with tofa-
citinib (LaBranche et al., 2012), although the effect of peficitinib has
yet to be determined. Previously, we and others reported that enhanced
cell–cell and cell–extracellular matrix interactions mediated by cad-
herin-11 and integrin α9, respectively, play essential roles in the
structural assembly of these structures (Emori et al., 2017; Kiener et al.,
2006). However, JAK inhibitors did not alter cadherin-11 or integrin α9
protein levels in the 3D-culture system (Fig. 4). Also, JAK inhibitors do
not affect adhesion of RA-FLS on plastic surface nor on endothelial cells
Fig. 6. Gene expression levels of pSTAT3-
inducing cytokines and growth factors in
RA- and OA-FLS. Total RNA from 3D-cul-
tured RA- and OA-FLS analyzed by micro-
array and expression levels of the indicated
genes are shown. Data represent the mean
and S.E.M. (n = 3)
EGF, epidermal growth factor; IL, inter-
leukin; LIF, leukemia inhibitory factor;
OSM, oncostatin M; PDGF, platelet-derived
growth factor.
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(Diller et al., 2019). JAK inhibitors might abrogate thickening of the
synovium by promoting apoptosis, although we have yet to determine
whether activation of STAT3 plays a crucial role in this process and
whether there is enhanced apoptosis in 3D-cultured RA-FLS treated
with JAK inhibitors. Notably, IL-6 receptor blockade (Fig. 4), like TNF-
α blockade (Emori et al., 2017), did not disrupt the hyperplastic lining-
like structure, emphasizing the unique action of JAK inhibitors in at-
tenuating synovial hyperplasia. We also showed that JAK inhibition
decreased spontaneous production of various pro-inflammatory med-
iators, including MMPs, IL-6, VEGF and TNFSF11 in 3D-cultured RA-
FLS (Fig. 5A and C). This is consistent with a previous report that
showed that ex vivo treatment of RA synovial explants with a JAK in-
hibitor decreases the production of pro-inflammatory mediators by al-
tering mitochondrial function (McGarry et al., 2018), which may pro-
vide a mechanistic explanation for these effects. MMPs synthesized by
RA-FLS cause damage to cartilage, whereas TNFSF11 expressed by RA-
FLS mediates bone destruction by inducing osteoclastogenesis (Guo
et al., 2018; Takayanagi et al., 2000). Upregulation of angiogenesis by
VEGF is also prevalent in RA and is crucial for the development of
pannus (Koch, 1998). Therefore, JAK inhibitors can ameliorate sus-
tained synovitis and subsequent joint destruction by modulating the
production of these pro-inflammatory mediators in RA-FLS.
Although the overall in vitro pharmacologic profile of peficitinib
was comparable to that of tofacitinib (Table 1), peficitinib might be
more advantageous for controlling joint inflammation than tofacitinib
at a clinically relevant dose. In a phase 2 clinical trial for RA, peficitinib
displayed a significant 50% improvement in the American College of
Rheumatology criteria (ACR50) response at oral doses of 100 and
150 mg (Takeuchi et al., 2016). Based on the maximum plasma con-
centration (Cmax) at 150 mg in healthy volunteers (613.2 ng/ml, As-
tellas Pharma, Inc.) and the protein-binding rate (72.83–75.20%, As-
tellas Pharma, Inc.), the unbound maximum plasma concentration
(Cmax, u) of peficitinib at this dose can be estimated as 466.0–510.4 nM
(152.1–166.6 ng/ml), which seems sufficient to ameliorate the patho-
genic activity of RA-FLS (Fig. 4A, D, 5A and 5C). In contrast, the esti-
mated Cmax, u of tofacitinib at the approved dose (5 mg) is below
100 nM according to published information (Lamba et al., 2016; Pfizer
Inc., 2012; Riese et al., 2010). Therefore, peficitinib may have higher
efficacy against synovial inflammation than tofacitinib under clinical
settings. In addition to the dosing advantage, peficitinib, but not tofa-
citinib, showed a trend towards decreasing STAT3 protein levels in RA-
FLS (Figs. 3A and 4D). Consistent with this, peficitinib showed more
potent induction of SNP-induced apoptosis (Fig. 3C) and more profound
reduction in the formation of lining-like structure (Fig. 4A) and IL-6 and
VEGF-A production by RA-FLS (Fig. 5A). Thus, increased STAT3 ex-
pression might be involved in these processes that are potentially more
sensitive to peficitinib than tofacitinib. While findings from a panel of
kinase assays (conducted by Carna Biosciences, Inc., Kobe, Japan;
Supplementary Table 1) have yet to establish a unique mechanism for
peficitinib, further investigation will be conducted to elucidate the
mechanism for the differential effects.
4.1. Conclusions
Our data demonstrate that constitutive activation of the JAK-STAT
pathway mediates the pro-inflammatory response and self-directed
aggressive behavior of RA-FLS.
The novel JAK inhibitor, peficitinib, suppressed activation of
STAT3, abrogated thickening of the synovium and inhibited production
of pro-inflammatory mediators in RA-FLS. These multiple effects could
not be achieved through inhibition of a single cytokine, which em-
phasizes the therapeutic value of JAK inhibitors in addressing persistent
synovitis and progression of joint destruction in RA.
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